1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDA Funding Opportunities (Trans-NIH) is sponsored by National Institute on Drug Abuse (NIDA) / National Institutes of Health (NIH). NIDA provides funding opportunities for research addressing substance use disorders, including drug and alcohol addiction. This encompasses basic and clinical research, as well as initiatives focused on prevention, treatment, and recovery.
Get alerted about grants like this
Save a search for “National Institute on Drug Abuse (NIDA) / National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
As of October 2025, the NIDA Funding App has been retired. The NIH announcement stating this change can be read here: NOT-OD-25-143 . NIDA Funding Strategy – A review of NIDA’s strategy for funding, based on programmatic priorities.
Notice of Special Interest (NOSI) - Formerly known as Drug Abuse Topics of Special/Continuing Interest (DAT) NIDA Challenges Program – Crowd-sourced opportunities for providing solutions for particular goals. Helping to End Addiction Long-term (HEAL) Initiative – Congressional initiative to address the opioid overdose crisis. NIDA International Program – International research collaboration opportunities on drug abuse and addiction.
See NIDA’s Resources for Grants & Contracts to learn more about applying for a grant and the pre-approval and approval process. Administrative Supplements for Grants & Cooperative Agreements Administrative Supplements for Grants & Cooperative Agreements – Additional funding to an active NIDA grant or cooperative agreement.
Supplemental Information for NOFOs Supplemental Information for NOT-DA-22-064: Notice of Intent to Publish a Funding Opportunity Announcement for NIH Brain Development Cohorts Biospecimen Access FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-24-007.
FAQs for Registry of Medical Cannabis Use and Health Outcomes: RFA-DA-23-011 Supplemental Information for NIH Developmental Studies Biospecimen Access Program FAQs for Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders - RFA-DA-23-014 Pre-Application Information Webinar for PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders FAQs Regarding Notice of Information: Establishment of a Standard THC Unit to be Used in Research (NOT-DA-21-049) Frequently Asked Questions about NOT-DA-21-041: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus RFA-DA-21-009: Pre-Application Webinar and FAQs- Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research - RFA-DA-20-025 FAQs for Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) FAQs for NOT-DA-19-003: HEAL Initiative: Request for Administrative Supplements to Existing Grants to Accelerate Research on Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) Supplemental Information (FAQs) for NIDA Research E-cigarette - PAR-17-156 Supplemental Information (FAQs) for RFA-DA-17-014 and RFA-DA-17-023
According to the current listing, eligibility includes: Eligibility varies by specific funding opportunity, but generally includes institutions of higher education, nonprofits, small businesses, and government entities engaged in research. Confirm the full requirements in the official notice before applying.
NIDA Funding Opportunities (Trans-NIH) is funded by National Institute on Drug Abuse (NIDA) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
BEHAVIORAL THERAPY DEVELOPMENT AND BEHAVIORAL SCIENCE is sponsored by National Institute on Drug Abuse (NIDA) / National Institutes of Health (NIH). This initiative encourages 'Stage I' behavioral therapy research based on knowledge gained and/or research paradigms from other areas of cognitive and behavioral science. Such translational research may be based on ideas, principles, and/or research paradigms in various areas including behavioral economics, cognition and cognitive biases, decision-making, emotion, memory, and motivation, with the aim of developing new or refining existing behavioral therapies for individuals in drug abuse treatment.
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) / National Institutes of Health (NIH). This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to develop Artificial Intelligence (AI)-related technologies for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder.
NIH HEAL Initiative Harm Reduction Research Network is sponsored by National Institute on Drug Abuse (NIDA) / National Institutes of Health (NIH). This initiative invests in research to reduce the overdose epidemic and improve care access for people who use drugs through the establishment of a harm reduction research network. Projects funded will test harm reduction interventions and assess existing harm reduction programs.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
The April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read articleNIH has no active SBIR or STTR omnibus solicitations for the first time in a decade. The FY26 reset reposts the omnibus series on June 1 with a September 8 deadline and a quietly historic change — Direct-to-Phase II STTR awards. Here is the strategy.
Read article